Exalenz Bioscience Ltd. announced that it received FDA approval for a joint clinical trial with Galectin Therapeutics Inc. The company's product, the BreathID, will be used to track and diagnose patients in a second-stage clinical trial of GR-MD-02, an experimental treatment for liver cirrhosis caused by NASH (fatty liver disease). Galectin Therapeutics is conducting a multicenter, double-blind, placebo-controlled Phase 2 trial with 156 patients to evaluate the safety and effect of the drug.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- ILa | -.--% | +1.39% | +107.88% |
1st Jan change | Capi. | |
---|---|---|
+107.88% | 45.97M | |
-5.56% | 181B | |
-0.11% | 108B | |
-6.17% | 66.12B | |
+2.64% | 50.65B | |
+6.58% | 43.11B | |
+3.49% | 40.74B | |
+21.98% | 31.6B | |
+16.38% | 25.56B | |
-5.81% | 24.16B |
- Stock Market
- Equities
- EXEN Stock
- News Exalenz Bioscience Ltd
- Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02